Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Early Phase II, Multicenter, Placebo-Controlled, Randomized, Double-Blind, Parallel-Group, Comparison Study to Investigate the Chemotherapy-Induced Peripheral Neuropathy (CIPN) Onset-Suppressing Effect and Safety of ONO-2910 in Patients With Breast Cancer Receiving Weekly Paclitaxel

NCT06538272 is registered in ClinicalTrials.gov with Ono Pharmaceutical Co., Ltd. as lead sponsor.

NCT NCT06538272
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06538272 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Early Phase II, Multicenter, Placebo-Controlled, Randomized, Double-Blind, Parallel-Group, Comparison Study to Investigate the Chemotherapy-Induced Peripheral Neuropathy (CIPN) Onset-Suppressing Effect and Safety of ONO-2910 in Patients With Breast Cancer Receiving Weekly Paclitaxel
Lead sponsor
Ono Pharmaceutical Co., Ltd.
Phase
Phase 2
Overall status
Completed
Start date
August 31, 2023
Completion date
September 19, 2024
Enrollment
210 (actual)
Sites
30

Conditions

As the registry lists them; a condition with its own page is linked.

cipn - chemotherapy-induced peripheral neuropathy